Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway

Liver International

Volumn 30, Issue 9, 2010, Pages 1315-1323

  Leung, Thomas Ho Yin ^a   Yam, Judy Wai Ping ^a,b   Chan, Lo Kong ^a   Ching, Yick Pang ^a   Ng, Irene Oi Lin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cell growth suppression; DLC2 (deleted in liver cancer 2); Hepatocellular carcinoma; Raf 1 ERK1 2 p70S6K signalling

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; PAXILLIN; RAF PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL CYCLE PROGRESSION; CELL MIGRATION; CONTROLLED STUDY; DELETED IN LIVER CANCER 2 GENE; FLOW CYTOMETRY; GENE ACTIVITY; GENE SILENCING; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIVER CELL CARCINOMA; MIGRATION INHIBITION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GTPASE-ACTIVATING PROTEINS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PAXILLIN; PROTO-ONCOGENE PROTEINS C-RAF; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 78349241737     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02307.x     Document Type: Article

References (31)

1. Ching YP, Wong CM, Chan SF, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003; 278: 10824-30.
2. Leung TH, Ching YP, Yam JW, et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 2005; 102: 15207-12.
3. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995; 269: 1270-2.
4. Yamamoto M, Marui N, Sakai T, et al. ADP-ribosylation of the rhoA gene product by botulinum C3 exoenzyme causes Swiss 3T3 cells to accumulate in the G1 phase of the cell cycle. Oncogene 1993; 8: 1449-55.
5. Waf1/Cip1. Nature 1998; 394: 295-9.
6. Welsh CF, Roovers K, Villanueva J, et al. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 2001; 3: 950-7.
7. Zuckerbraun BS, Shapiro RA, Billiar TR, Tzeng E. RhoA influences the nuclear localization of extracellular signal-regulated kinases to modulate p21Waf/Cip1 expression. Circulation 2003; 108: 876-81.
8. Hirai A, Nakamura S, Noguchi Y, et al. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997; 272: 13-6.
9. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999; 274: 21926-31.
10. Rivard N, Boucher MJ, Asselin C, L'Allemain G. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol 1999; 277 (Part 1): C652-64.
11. Weber JD, Hu W, Jefcoat SCJR., et al. Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 1997; 272: 32966-71.
12. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810-6.
13. Osada S, Kanematsu M, Imai H, et al. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg 2005; 201: 405-11.
14. Shields JM, Pruitt K, Mcfall A, et al. Understanding ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000; 10: 147-54.
15. Bessard A, Fremin C, Ezan F, et al. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol 2007; 212: 526-36.
16. Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-5.
17. Hui IC, Tung EK, Sze KM, et al. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int 2010; 30: 65-75.
18. Hirakawa M, Oike M, Karashima Y, Ito Y. Sequential activation of RhoA and FAK/paxillin leads to ATP release and actin reorganization in human endothelium. J Physiol 2004; 558 (Part 2): 479-88.
19. Flinn HM, Ridley AJ. Rho stimulates tyrosine phosphorylation of focal adhesion kinase, p130 and paxillin. J Cell Sci 1996; 109 (Part 5): 1133-41.
20. Petit V, Boyer B, Lentz D, et al. Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol 2000; 148: 957-70.
21. Cary LA, Chang JF, Guan JL. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci 1996; 109 (Part 7): 1787-94.
22. Kim TY, Lee JW, Kim HP, et al. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun 2007; 355: 72-7.
23. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell 2000; 103: 227-38.
24. Zohn IM, Campbell SL, Khosravi-Far R, et al. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 1998; 17: 1415-38.
25. Mammoto A, Huang S, Moore KOHP, Ingber DE. Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition. J Biol Chem 2004; 279: 26323-30.
26. Seasholtz TM, Zhang T, Morissette MR, et al. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res 2001; 89: 488-95.
27. Gysin S, Lee SH, Dean NM, Mcmahon M. Pharmacologic inhibition of RAF →MEK→ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res 2005; 65: 4870-80.
28. Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17: 1263-93.
29. Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997; 9: 174-9.
30. Li W, Chong H, Guan KL. Function of the Rho family GTPases in Ras-stimulated Raf activation. J Biol Chem 2001; 276: 34728-37.
31. Yau TO, Leung TH, Lam S, et al. Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PLoS One 2009; 4: e6566.